Early promising results of anti-CTLA-4, ipilimumab, and anti-PD-1, pembrolizumab and nivolumab, demonstrated that ipilimumab compared favorably to the current standard melanoma therapies of the time including gp100 peptide vaccine and improved overall survival (OS) (17). Here, CTLA4 is linked to melanoma.